Abstract

BackgroundGenome-wide transcriptome profiling generated by microarray and RNA-Seq often provides deregulated genes or pathways applicable only to larger cohort. On the other hand, individualized interpretation of transcriptomes is increasely pursued to improve diagnosis, prognosis, and patient treatment processes. Yet, robust and accurate methods based on a single paired-sample remain an unmet challenge.Methods"N-of-1-pathways" translates gene expression data profiles into mechanism-level profiles on single pairs of samples (one p-value per geneset). It relies on three principles: i) statistical universe is a single paired sample, which serves as its own control; ii) statistics can be derived from multiple gene expression measures that share common biological mechanisms assimilated to genesets; iii) semantic similarity metric takes into account inter-mechanisms' relationships to better assess commonality and differences, within and cross study-samples (e.g. patients, cell-lines, tissues, etc.), which helps the interpretation of the underpinning biology.ResultsIn the context of underpowered experiments, N-of-1-pathways predictions perform better or comparable to those of GSEA and Differentially Expressed Genes enrichment (DEG enrichment), within-and cross-datasets. N-of-1-pathways uncovered concordant PTBP1-dependent mechanisms across datasets (Odds-Ratios≥13, p-values≤1 × 10−5), such as RNA splicing and cell cycle. In addition, it unveils tissue-specific mechanisms of alternatively transcribed PTBP1-dependent genesets. Furthermore, we demonstrate that GSEA and DEG Enrichment preclude accurate analysis on single paired samples.ConclusionsN-of-1-pathways enables robust and biologically relevant mechanism-level classifiers with small cohorts and one single paired samples that surpasses conventional methods. Further, it identifies unique sample/ patient mechanisms, a requirement for precision medicine.

Highlights

  • Genome-wide transcriptome profiling generated by microarray and RNA-Seq often provides deregulated genes or pathways applicable only to larger cohort

  • We evaluated the robustness of the N-of-1-pathways method in three transcriptome profile datasets: a single paired sample (RNA-Seq from mouse neuronal cell line, Dataset I) and two small sets of paired samples

  • Concordance of PTBP1-KD associated mechanisms unveiled by N-of-1-pathways and Fisher’s Exact Test (FET) Enrichment in neuronal cell line We first performed an independent within-study analysis from published RNA-Seq transcriptome profile of PTBP1-depleted neuronal cell lines (Dataset I; Table 2; Figure 2)

Read more

Summary

Introduction

Genome-wide transcriptome profiling generated by microarray and RNA-Seq often provides deregulated genes or pathways applicable only to larger cohort. On the other hand, individualized interpretation of transcriptomes is increasely pursued to improve diagnosis, prognosis, and patient treatment processes. The variability of individual patients at the molecular response to therapy or tissue specific-dependent mechanisms. Methods are required to empower mechanism-level analysis on a single pairs of samples (tumor vs matched control, primary tumor vs metastases, before vs after treatment samples, etc.). The advent of the increased dynamic range and accuracy of RNA-Sequencing over expression arrays [1,2] provides a new opportunity for studying single subject transcriptomes [3]. While molecular biomarker discovery in N-of-1 studies may appear unfeasible, investigation may be headed towards mechanisms and pathways analysis. Mechanisms-classifiers were shown to outperform gene-level classifiers in addition to reproducible results and advanced understanding of the underpinning biology [4,5]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.